Eurofins Scientific stock among the strongest gainers of the CAC 40, approaching €74
While the CAC 40 loses ground during the session, Eurofins Scientific stands out and ranks among the strongest gainers of the index. The group specializing in scientific testing and analysis services is benefiting from an upward momentum that extends a rebound initiated several weeks ago, despite a market environment weighed down by geopolitical tensions in the Middle East and rising bond yields.
A stock establishing itself above its moving averages in a declining CAC 40
Eurofins Scientific gains 1.76% to €74.06 during the session, bucking a CAC 40 that is falling 0.42%. This movement places the stock among the strongest gainers of the index, alongside values such as Publicis Groupe and Legrand. Technically, the stock is positioned comfortably above its three moving averages: above the 20-day MA at €71.41 (a gap of nearly 4%), above the 50-day MA at €69.80 and more than 13% above the 200-day MA at €65.29.
This bullish configuration is accompanied by an RSI at 59, still far from the overbought threshold at 70, which leaves room before reaching a tension zone. The stock is, however, bumping up against resistance at €74.08, virtually at current levels, whose breakthrough would signal a continuation of the current momentum.
Encouraging half-year results and 20% year-on-year growth as a backdrop
In terms of stock performance, Eurofins Scientific shows a gain of 8.66% over the month and 20.74% over three months, a substantial rebound that contrasts with the decline recorded in spring, when the stock had lost nearly 11% in one week following quarterly revenues deemed disappointing. When publishing H1 2026 results on July 23, 2026, management had struck a confident tone: profitability was now approaching the target set for 2027, with reduced investments contributing to significantly improving cash generation. Among the points of concern identified at that time, organic revenue growth had not yet returned to a normal pace, and ancillary activities of the BioPharma division in North America remained lagging.
The expected recovery of these activities in the second half of 2026, as well as the acquisition of Element Materials Technology, whose completion was anticipated in the fourth quarter of 2026 with over $150 million in annual revenues, constitutes a key element to monitor. The analysts' consensus on the value remains worth monitoring in this rebound context, as the €74.08 resistance represents the next threshold to break through to confirm the trend.
